Seizure frequency data were analyzed in patients who were randomized to and completed the 13-week Maintenance Period of the phase III studies on perampanel 8mg , and who received an actual ( last ) dose of 12mg during ( 1 ) the extension 16-week blinded Conversion Period or ( 2 ) weeks 1-13 of the extension Maintenance Period .